Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States
Authors:
- Rena M. ContiRCRena M. Conti
- Stacie B. DusetzinaSDStacie B. Dusetzina
- Jonathan OberlanderJOJonathan Oberlander
Open Access
- 14 July 2022
- journal article
- research article
- Published by Duke University Press in Journal of Health Politics, Policy and Law
- Vol. 47 (6) , 691-708
Abstract
State payers may face financial incentives to restrict use of high-cost medications. Yet, restrictions on access to high-value medications may have deleterious effects on population health. Direct-acting antivirals (DAAs), available since 2013, can cure chronic infection with hepatitis C virus (HCV). With prices upward of $90,000 for a treatment course, states have struggled to ensure access to DAAs for Medicaid beneficiaries and the incarcerated, populations with a disproportionate share of HCV. Advance purchase commitments (APCs), wherein a payer commits to purchase a certain quantity of medications at lower prices, offer payers incentives to increase access to high-value medications while also offering companies guaranteed revenue. This article discusses the use of subscription models, a type of APC, to support increased access to high-value DAAs for treating HCV. First, the authors provide background information about HCV, its treatment, and state financing of prescription medications. They then review the implementation of HCV subscription models in two states, Louisiana and Washington, and the early evidence of their impact. The article discusses challenges to evaluating state-sponsored subscription models, and it concludes by discussing implications of subscription models that target DAAs and other high-value, high-cost medicines.Keywords
This publication has 32 references indexed in Scilit:
- Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus EthicsAmerican Journal of Public Health, 2017
- Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis CAmerican Journal of Gastroenterology, 2017
- Evaluating the Health Impact of Large-Scale Public Policy Changes: Classical and Novel ApproachesAnnual Review of Public Health, 2017
- Reinventing HCV Treatment: Past and Future PerspectivesThe Journal of Clinical Pharmacology, 2016
- Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the USBMC Gastroenterology, 2015
- National trends in prescription drug expenditures and projections for 2015American Journal of Health-System Pharmacy, 2015
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United StatesAnnals of Internal Medicine, 2015
- Best Practices in Quasi–Experimental Designs: Matching Methods for Causal Inference2008
- Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS)Medical Care, 2007
- Studying Prescription Drug Use and Outcomes With Medicaid Claims DataMedical Care, 2007